Page 97 - Read Online

Selvakumar et al. IMT post LDLT-report of first case

In our case, multiple preoperative biopsies were Financial support and sponsorship
not confirmatory and led to delay in treatment. Final None.
excision biopsy was subjected to extensive evaluation
with IHC panel which included c-KIT, ALK, CD117, CD Conflicts of interest
45, CK-7, neuron specific enolase, chromogranin, alpha There are no conflicts of interest.
fetal protein, desmin, actin. The tumor in this case was
negative for other IHC markers including those specific Patient consent
for hepatocellular carcinoma, cholangiocarcinoma, Patient consent was received.
neuroendocrine tumors, gastrointestinal stromal
tumors and lymphomas. However, the tumor had Ethics approval
classic characteristics of IMT along with positive IHC Since it is not a study and just a report, ethical approval
for anti-lymphoma kinase. Complete tumor excision is is not needed as per our hospital policies.
curative in most cases. However recurrence at new
[7]
sites can be prevalent. Ceritinibis a tyrosine kinase REFERENCES
inhibitor accepted for treating tumors positive for ALK.
[8]
The patient was given ceritinib for 1 year. Follow-up 1. Pillai AA. Management of de novo malignancies after liver
with PET CT at 1 year revealed no recurrence. Hence transplantation. Transplant Rev (Orlando) 2015;29:38-41.
ceritinib was discontinued. At 2 years, the child is 2. Piselli P, Busnach G, Fratino L, Citterio F, Ettorre GM, De Paoli P,
disease free with good graft function. Serraino D; Immunosuppression and Cancer Study Group. De novo
malignancies after organ transplantation: focus on viral infections.
Curr Mol Med 2013;13:1217-27.
In conclusion: (1) although IMTs are rare, it is a 3. Lykavieris P, Fabre M, Waguet J, Bernard O. Inflammatory
serious complication after liver transplantation; (2) pseudotumor after liver transplantation. J Pediatr Gastroenterol Nutr
only one case has been reported in the literature so 2000;31:309-12.
far after liver transplantation that too after DDLT; (3) 4. Bronzino P, Abbo L, Bagnasco F, Barisone P, Dezzani C, Genovese
in this case report we have described the first case AM, Iannucci P, Ippoliti M, Sacchi M, Aimo I. Intra-abdominal
of IMT after LDLT; (4) definitive histologic evidence inflammatory myofibroblastic pseudotumor: case report and review of
the literature. G Chir 2005;26:362-4.
is essential in their diagnosis and differentiation from 5. Tufan A, Bahat G. Inflammatory pseudotumors after stem cell
other malignant tumors; and (5) IHC based targeted transplantation. Hematol Rep 2015;7:5848.
therapy may be helpful as adjuvant. 6. Lykavieris P, Fabre M, Waguet J, Bernard O. Inflammatory
pseudotumor after liver transplantation. J Pediatr Gastroenterol Nutr
Authors’ contributions 2000;31:309-12.
Doing surgery and writing of this manuscript: N. 7. Vroobel K, Judson I, Dainton M, McCormick A, Fisher C, Thway K.
Selvakumar ALK-positive inflammatory myofibroblastic tumor harboring ALK
gene rearrangement, occurring after allogeneic stem cell transplant in
Preparing the slides for histopathology: P. Saboti an adult male. Pathol Res Pract 2016;212:743-6.
Reporting of HPE: S. Kaul 8. Chaudhary P. Mesenteric inflammatory myofibroblastic tumors. Ann
Chief surgeon in charge of the case: S. Gupta Gastroenterol 2015;28:49-54.

Hepatoma Research ¦ Volume 3 ¦ May 17, 2017 89